Skip to content

OsseoFit™ Prospective Data Collection

OsseoFit™ Porous Tissue Matrix™ Prospective Data Collection

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00708474
Enrollment
0
Registered
2008-07-02
Start date
2008-06-30
Completion date
2009-02-28
Last updated
2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Graft, Knee

Keywords

Bone graft, Bone void filler, Bone plug, OsseoFit™, knee, bone graft sites in the knee

Brief summary

This study compares the fill of bone graft sites in the knee. It is hypothesized that harvest sites, voids, and defects caused by trauma that are treated with the OsseoFit™ Porous Tissue Matrix™ device will achieve a better fill grade than those treated with the conventional method.

Interventions

DEVICEOsseoFit™ Porous Tissue Matrix™

Bone void filler

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* The OsseoFit™ Porous Tissue Matrix™ is intended to be gently packed into the bony voids or gaps of the extremities and pelvis caused by trauma or surgery and are not intrinsic to the stability of the bony structure. These defects may be created from repetitive motion or traumatic injury to the bone or surgically created osseous defects for the harvest of bone. The device is a bone void filler that resorbs and is replaced with bone during the healing process. The device may be combined with sterile fluids such as saline or autogenous blood products such as blood, platelets, or bone marrow aspirate. The addition of these autogenous blood products does not compromise the performance of the device. Hydration with biologically beneficial sterile fluids can potentially have a positive influence on the healing and replacement of the device with bone.

Exclusion criteria

* Infection at site * Hypercalcemia * Known allergies to bovine collagen * Current osteomyelitis at operative site * Systemic conditions which affect bone and/or wound healing * Known severe allergies manifested by history of anaphylaxis * Desensitization treatment injections to meat products, as injections may contain bovine collagen * Severe degenerative bone disease

Design outcomes

Primary

MeasureTime frame
Site repair grade by MRI analysis6 months

Secondary

MeasureTime frame
Site repair grade by MRI analysis3 months, 1 year
Pain Score3 months, 6 months, 1 year
Function Score3 months, 6 months, 1 year
Physical Evaluation3 months, 6 months, 1 year
Incidence of adverse eventsAny time

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026